Vitiligo expansion and extent correlate with durable response in anti‐programmed death 1 antibody treatment for advanced melanoma: A multi‐institutional retrospective study
- 10 April 2020
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (6), 629-635
- https://doi.org/10.1111/1346-8138.15345
Abstract
Vitiligo is an autoimmune disorder resulting from the destruction of melanocytes. Several reports indicate the association between vitiligo and treatment response in advanced melanoma during immunotherapy. It has not been investigated, however, if an increase of vitiligo while on treatment with anti‐programmed death 1 (PD‐1) antibodies is associated with more durable responses. The aim of this study is to evaluate the correlation between the vitiligo dynamics and clinical efficacy of anti‐PD‐1 antibodies. This study included advanced melanoma patients who were treated with nivolumab or pembrolizumab and developed vitiligo thereafter. Correlation between vitiligo expansion (defined as an increase of lesion size at two separate time points at least 4 weeks apart) as well as vitiligo extent (body surface area [BSA] affected) and clinical efficacy based on response rate, progression‐free survival and overall survival was assessed. We retrospectively reviewed 29 patients. The median time from the initiation of anti‐PD‐1 antibody to vitiligo onset was 4.3 months in patients who showed a response and 5.5 months in patients who showed no response (P = 0.31). Twelve patients showed vitiligo expansion, and in nine of these patients, vitiligo increased to grade 2 (covering ≥ 10% BSA). Vitiligo expansion and grade 2 vitiligo showed no improvement in treatment response (P = 0.59 and 0.25) but were associated with prolonged progression‐free survival (P = 0.019 and 0.04). Grade 2 vitiligo also showed a trend for prolonged overall survival (P = 0.07). Trend of expansion and larger vitiligo extent may be predictive factors of prolonged survival during anti‐PD‐1 antibody in melanoma patients.Keywords
Funding Information
- National Cancer Center Research and Development Fund (29-A-3)
This publication has 26 references indexed in Scilit:
- Immunopathogenesis of vitiligoAutoimmunity Reviews, 2011
- Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort studyAnnals of Oncology, 2009
- Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II MelanomaJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Enhanced Survival Associated with Vitiligo Expression during Maintenance Biotherapy for Metastatic MelanomaJournal of Investigative Dermatology, 2006
- Prognostic Significance of Autoimmunity during Treatment of Melanoma with InterferonThe New England Journal of Medicine, 2006
- Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With AutologousGM-CSF–Transduced Tumor Cells in Metastatic Melanoma PatientsJournal of Clinical Oncology, 2005
- Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?Pigment Cell Research, 2005
- Vitiligo in Patients with MelanomaJournal of Immunotherapy, 1996
- Vitiligo and Cutaneous MelanomaDermatology, 1991